• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA approves generic levofloxacin

Article

The FDA has granted final approval to Hi-Tech Pharmacal Co. Inc. for the company's abbreviated new drug application for levofloxacin ophthalmic solution 0.5%, the generic for a proprietary ophthalmic solution (Quixin, Vistakon). The product is indicated for bacterial conjunctivitis.

Amityville, NY-The FDA has granted final approval to Hi-Tech Pharmacal Co. for the company's abbreviated new drug application for levofloxacin ophthalmic solution 0.5%, the generic version of a proprietary ophthalmic solution (Quixin, Vistakon). The product is indicated for bacterial conjunctivitis.

The proprietary ophthalmic solution had sales of $2 million for the 12 months ended in December 2010, according to IMS sales data. Hi-Tech Pharmacal is preparing to launch its generic version by the end of March 2011.

Hi-Tech Pharmacal is a specialty pharmaceutical company manufacturing generic and branded prescription and over-the-counter products. According to the company, it has 15 products awaiting approval at the FDA and targeting brand and generic sales of more than $1.0 billion, as well as 20 products in active development targeting brand sales of more than $2 billion, including sterile ophthalmic products.

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.